Detailed Information

Cited 43 time in webofscience Cited 0 time in scopus
Metadata Downloads

Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

Authors
Mansur, Rodrigo B.Zugman, AndreAhmed, JuhieCha, Danielle S.Subramaniapillai, MehalaLee, YenaLovshin, JulieLee, Jung G.Lee, Jae HonDrobinin, VladislavNewport, JasonBrietzke, ElisaReininghaus, Eva Z.Sim, KangVinberg, MajRasgon, NatalieHajek, TomasMcIntyre, Roger S.
Issue Date
Nov-2017
Publisher
ELSEVIER SCIENCE BV
Keywords
Glucagon-like peptide−1; Gray matter volume; Liraglutide; Mood disorders; Neuroimaging; Weight loss.
Citation
EUROPEAN NEUROPSYCHOPHARMACOLOGY, v.27, no.11, pp 1153 - 1162
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume
27
Number
11
Start Page
1153
End Page
1162
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/34145
DOI
10.1016/j.euroneuro.2017.08.433
ISSN
0924-977X
1873-7862
Abstract
Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function.
Files in This Item
There are no files associated with this item.
Appears in
Collections
5. Others > Others(Medicine) > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE